Palisade Bio, Inc. (PALI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PALI
- Company Palisade Bio, Inc.
- Price $1.94
- Changes Percentage -4.43
- Change -0.09
- Day Low $1.94
- Day High $2.08
- Year High $2.64
- Year Low $0.53
- Market Cap $286,086,163
- Price Avg 50 EMA (D) $1.82
- Price Avg 200 EMA (D) $1.37
- Exchange NASDAQ
- Volume 4,565,785
- Average Volume 4,628,859
- Open $2.01
- Previous Close $2.03
- EPS -2.07
- PE -0.93
- Earnings Announcement 2026-03-25 12:00:00
- Shares Outstanding $149,003,210
Company brief: PALISADE BIO, INC. (PALI )
- Healthcare
- Biotechnology
- Mr. J. D. Finley
- https://www.palisadebio.com
- US
- N/A
- 03-30-2007
- US6963892046
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.